AORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Artivion Inc (AORT) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown revenue growth in its latest quarter, the significant drop in net income and EPS, coupled with bearish technical indicators and lack of strong trading signals, suggests a cautious approach. The absence of recent news or strong positive catalysts further supports a hold recommendation.
The stock's technical indicators are mixed to bearish. The MACD is slightly positive but contracting, RSI is neutral at 41.521, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 35.453, and resistance is at 37.752. The stock is trading close to its pivot level of 36.603, indicating limited momentum.
Analysts maintain a Buy rating despite lowering the price target to $48, citing strong growth in aortic stent grafts and On-X products.
Net income dropped significantly by -114.73% YoY, and EPS fell by -112.82% YoY. Gross margin slightly declined, and there are no significant trading trends or recent news to act as a catalyst. Technical indicators are bearish, and no recent congress trading data is available.
In Q4 2025, revenue increased by 19.20% YoY to $115.99M, but net income dropped by -114.73% YoY to $2.42M. EPS also fell by -112.82% YoY to $0.05, and gross margin slightly declined to 63.06%.
Canaccord analyst William Plovanic lowered the price target to $48 from $51 but maintained a Buy rating. The firm highlighted strong Q4 performance despite a one-time revenue reduction and expects growth in key product lines like aortic stent grafts and On-X.
